Complexin-1 inhibitors belong to a class of chemical compounds that specifically target and modulate the function of the protein complexin-1. Complexin-1 is a crucial regulatory protein involved in synaptic neurotransmitter release in the nervous system. When neurons communicate with each other, they release neurotransmitters into the synapses, where these chemical messengers bind to receptors on the postsynaptic neuron, transmitting signals between neurons. Complexin-1 plays a vital role in this process by fine-tuning the timing and precision of neurotransmitter release. It forms a complex with SNARE proteins, which are essential for vesicle fusion and neurotransmitter release, and helps to regulate the fusion machinery. Complexin-1 inhibitors are designed to interact with complexin-1, disrupting its normal function and interfering with the tightly regulated synaptic vesicle release process. By doing so, these inhibitors can modulate synaptic activity and neurotransmission. The development of complexin-1 inhibitors has been of significant interest in the field of neuroscience, as they offer a unique opportunity to study and manipulate synaptic function and plasticity.
The chemical structures of complexin-1 inhibitors vary widely, ranging from small molecules to peptides and naturally occurring compounds. Some inhibitors are designed based on the specific binding interface of complexin-1 with SNARE proteins, aiming to block this interaction and prevent efficient neurotransmitter release. Others may target other regions of complexin-1, interfering with its conformational changes or regulatory interactions with other synaptic proteins. These diverse chemical structures allow researchers to explore different aspects of complexin-1 function and its impact on synaptic transmission. Laboratory studies using complexin-1 inhibitors have provided valuable insights into the fundamental mechanisms of neurotransmitter release and synaptic plasticity. By manipulating complexin-1 activity, researchers have been able to decipher the intricate processes governing synaptic vesicle fusion, calcium-dependent release, and short-term synaptic plasticity. These studies have deepened our understanding of how neurons communicate and how alterations in synaptic function can contribute to various neurological conditions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Huperzine A | 102518-79-6 | sc-200183 sc-200183A | 1 mg 5 mg | $140.00 $355.00 | 1 | |
A natural compound found in Chinese club moss (Huperzia serrata), huperzine A has been found to inhibit complexin-1 and acetylcholinesterase, making it a potential dual target compound for neurodegenerative diseases. | ||||||
Naproxen | 22204-53-1 | sc-200506 sc-200506A | 1 g 5 g | $24.00 $40.00 | ||
A chiral variant of the nonsteroidal anti-inflammatory agent (NSAID) naproxen, which has shown complexin-1 inhibitory effects in addition to its anti-inflammatory properties. | ||||||
Riluzole | 1744-22-5 | sc-201081 sc-201081A sc-201081B sc-201081C | 20 mg 100 mg 1 g 25 g | $20.00 $189.00 $209.00 $311.00 | 1 | |
An approved agent for amyotrophic lateral sclerosis (ALS), riluzole has been found to inhibit complexin-1 and modulate synaptic vesicle exocytosis. | ||||||
5,5-Diphenyl Hydantoin | 57-41-0 | sc-210385 | 5 g | $70.00 | ||
An antiepileptic agent, phenytoin has been shown to affect complexin-1 function and synaptic transmission. | ||||||